v3.26.1
Consolidated Statements of Operations - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2024
Dec. 31, 2025
Dec. 31, 2024
Revenue       $ 7,806,000
Operating Expenses:          
Research and development $ 3,000 $ 19,000   38,000 7,166,000
General and administrative 1,289,000 1,828,000   5,131,000 7,785,000
Loss on MannKind Transaction       2,618,000
Total operating expenses 1,292,000 1,847,000   5,169,000 17,569,000
Loss from operations (1,292,000) (1,847,000)   (5,169,000) (9,763,000)
Other income (expense):          
Interest income 12,000 53,000   144,000 467,000
Fair value adjustment of warrants 66,000   67,000 (67,000)
Other income (expense), net 108,000 (80,000)   (204,000) (196,000)
Total other income (expense), net 120,000 39,000   7,000 204,000
Income tax provision (benefit)        
Net loss $ (1,172,000) $ (1,808,000)   $ (5,162,000) $ (9,559,000)
Net loss per share - basic $ (0.32) $ (0.50)   $ (1.41) $ (2.62)
Net loss per share - diluted $ (0.32) $ (0.50)   $ (1.41) $ (2.62)
Weighted-average common shares outstanding - basic 3,652,285 3,652,285   3,652,285 3,652,285
Weighted-average common shares outstanding - diluted 3,652,285 3,652,285   3,652,285 3,652,285
Eos SENOLYTIXS Inc [Member]          
Revenue  
Operating Expenses:          
Research and development 449,183 23,225 8,970 35,225  
General and administrative 133,249 55,536 67,925 217,795  
Total operating expenses 582,432 78,761 76,895 253,020  
Other income (expense):          
Net loss before income tax provision (benefit) 582,432 78,761 76,895 253,020  
Income tax provision (benefit)  
Net loss $ (582,432) $ (78,761) $ (76,895) $ (253,020)  
Net loss per share - basic $ (0.12) $ (0.02) $ (0.07) $ (0.05)  
Net loss per share - diluted $ (0.12) $ (0.02) $ (0.07) $ (0.05)  
Weighted-average common shares outstanding - basic 5,000,000 5,000,000 1,068,493 5,000,000  
Weighted-average common shares outstanding - diluted 5,000,000 5,000,000 1,068,493 5,000,000